DE68900356D1 - Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt. - Google Patents

Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.

Info

Publication number
DE68900356D1
DE68900356D1 DE8989109381T DE68900356T DE68900356D1 DE 68900356 D1 DE68900356 D1 DE 68900356D1 DE 8989109381 T DE8989109381 T DE 8989109381T DE 68900356 T DE68900356 T DE 68900356T DE 68900356 D1 DE68900356 D1 DE 68900356D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
composition containing
dihydropyridine derivative
dihydropyridine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989109381T
Other languages
English (en)
Inventor
Ltd Miyajima
Ltd Yamaguchi
Takao Nissan Chemic Tsunematsu
Toshihisa Nissan Chemical Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Original Assignee
Zeria Pharmaceutical Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd, Nissan Chemical Corp filed Critical Zeria Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE68900356D1 publication Critical patent/DE68900356D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE8989109381T 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt. Expired - Fee Related DE68900356D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13226288 1988-05-30
JP1050471A JP2528706B2 (ja) 1988-05-30 1989-03-02 ジヒドロピリジン化合物の製剤組成物

Publications (1)

Publication Number Publication Date
DE68900356D1 true DE68900356D1 (de) 1991-11-28

Family

ID=26390939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8989109381T Expired - Fee Related DE68900356D1 (de) 1988-05-30 1989-05-24 Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.

Country Status (8)

Country Link
US (1) US4983593A (de)
EP (1) EP0344603B1 (de)
JP (1) JP2528706B2 (de)
CA (1) CA1332152C (de)
DE (1) DE68900356D1 (de)
ES (1) ES2051920T3 (de)
GR (1) GR3003615T3 (de)
NZ (1) NZ229309A (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (de) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
KR100457273B1 (ko) * 1996-03-18 2005-04-08 닛산 가가쿠 고교 가부시키 가이샤 에포니디핀염산염제제의제조방법
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
EP1741424B1 (de) 1997-08-11 2018-10-03 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
EP1027886B1 (de) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU762291B2 (en) 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
AU2583401A (en) * 1999-12-20 2001-07-03 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
JP2008501009A (ja) 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 性能を高めた医薬組成物
EP1829549A1 (de) * 2004-12-17 2007-09-05 Ono Pharmaceutical Co., Ltd. Amorphe zusammensetzung
EP1923051A4 (de) * 2005-09-06 2012-12-19 Astellas Pharma Inc Mikroteilchen einer schwerlöslichen substanz mit enterischem basismaterial, das auf der oberfläche der substanz adsorbiert ist
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US20100240711A1 (en) 2007-09-21 2010-09-23 Shionogi & Co., Ltd. Solid preparation comprising npyy5 receptor antagonist
EP2223702B1 (de) * 2007-12-03 2019-05-08 Tomita Pharmaceutical Co., Ltd. Kernteilchen für eine pharmazeutische zubereitung
WO2009140105A2 (en) 2008-05-14 2009-11-19 Merck & Co., Inc. Formulations for cathepsin k inhibitors
WO2010114928A2 (en) 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110064806A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP5792807B2 (ja) 2010-06-14 2015-10-14 ダウ グローバル テクノロジーズ エルエルシー アセテートおよびサクシネートの置換が向上されたヒドロキシプロピルメチルセルロースアセテートサクシネート
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
BR112013022788A2 (pt) 2011-03-08 2016-12-06 Zalicus Pharmaceuticals Ltd "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona"
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2837391B1 (de) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (de) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Verbindungen zur behandlung von immun- und entzündungserkrankungen
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018175648A1 (en) * 2017-03-21 2018-09-27 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773A4 (de) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948810A (ja) 1982-09-10 1984-03-21 Sony Corp 磁性記録体におけるデ−タのマスク及び再生方法
JPS62123117A (ja) 1985-11-22 1987-06-04 Nippon Chemiphar Co Ltd 塩酸ニカルジピン経口用組成物
CN1016063B (zh) * 1986-01-22 1992-04-01 日产化学工业株式会社 二氢吡啶-5-膦酸环亚丙基酯的制备
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
JP2528706B2 (ja) 1996-08-28
GR3003615T3 (de) 1993-03-16
US4983593A (en) 1991-01-08
EP0344603A1 (de) 1989-12-06
NZ229309A (en) 1991-06-25
EP0344603B1 (de) 1991-10-23
JPH0249728A (ja) 1990-02-20
CA1332152C (en) 1994-09-27
ES2051920T3 (es) 1994-07-01

Similar Documents

Publication Publication Date Title
DE68900356D1 (de) Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.
DE68901417D1 (de) Pharmazeutische zusammensetzung.
DE122004000023I2 (de) Pharmazeutische Zusammensetzung
DE3863963D1 (de) Pharmazeutische zusammensetzungen.
FI892640A (fi) Menetelmä piperidinoalkanoli-ibuprofeeniyhdistelmää sisältävän farmaseuttisen koostumuksen valmistamiseksi
DE3868986D1 (de) Pharmazeutische zusammensetzungen.
ATA129892A (de) Pharmazeutische zusammensetzung
DK229489A (da) Laegemiddeladsorbater
DE69101931T2 (de) Pharmazeutische Zusammensetzung.
DE69006094T2 (de) Pharmazeutische Zusammensetzungen.
IT8820386A0 (it) Composizioni farmaceutiche orosolubili contenti acetilcisteina.
NL192832B (nl) 1,8 gebrugde 6-halogeen-4-chinolon-3-carbonzuurderivaten en farmaceutisch preparaat dat een dergelijk derivaat bevat.
FI893643A (fi) Farmaceutiska kompositioner.
DE68918847D1 (de) Stabile pharmazeutische zusammensetzung.
NL194827B (nl) Thieno-triazolo-diazepinederivaten en farmaceutische preparaten die een dergelijk derivaat bevatten.
DK128589D0 (da) Anvendelse af piperidinmethanolderivater til fremstilling af et farmaceutisk praeparat
EP0406739A3 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
ATA225988A (de) Selbstfaerbestempel
IT1221493B (it) Composizioni farmaceutiche a cessione ritardata
ATE102034T1 (de) Ein piperidinylalkanolantihistaminikum enthaltende fluessige arzneizubereitungen.
DE68915203D1 (de) Pharmazeutische Mischungen.
ATA133288A (de) Pharmazeutische zusammensetzung
DE58905160D1 (de) Pharmazeutische zubereitung.
ATE68699T1 (de) Pharmazeutische zusammensetzung die ein dihydropyridinderivat enthaelt.
ATE78161T1 (de) 4-aroylimidazol-2-on enthaltende pharmazeutische zusammensetzung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee